Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer

MA Rice, SV Malhotra, T Stoyanova - Frontiers in oncology, 2019 - frontiersin.org
Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …

Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications

U Testa, G Castelli, E Pelosi - Medicines, 2019 - mdpi.com
Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

[HTML][HTML] Drugging the 'undruggable'. Therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods

M Radaeva, AT Ton, M Hsing, F Ban, A Cherkasov - Drug discovery today, 2021 - Elsevier
Transcription factors (TFs) act as major oncodrivers in many cancers and are frequently
regarded as high-value therapeutic targets. The functionality of TFs relies on direct protein …

ETS transcription factors as emerging drug targets in cancer

M Hsing, Y Wang, PS Rennie, ME Cox… - Medicinal research …, 2020 - Wiley Online Library
The ETS family of proteins consists of 28 transcription factors, many of which have been
implicated in development and progression of a variety of cancers. While one family …

Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy

F Fontana, M Anselmi, P Limonta - Cancer Letters, 2022 - Elsevier
Prostate cancer remains one of the most lethal malignancies among men worldwide.
Although the primary tumor can be successfully managed by surgery and radiotherapy …

ETS factors in prostate cancer

C Qian, D Li, Y Chen - Cancer letters, 2022 - Elsevier
The ETS family of proteins consists of 28 transcription factors, many of which play critical
roles in both normal tissue development and homeostasis and have been implicated in …

Past, current, and future strategies to target ERG fusion-positive prostate cancer

F Lorenzin, F Demichelis - Cancers, 2022 - mdpi.com
Simple Summary In addition to its role in development and in the vascular and
hematopoietic systems, ERG plays a central role in prostate cancer. Approximately 40–50 …

Extensive germline-somatic interplay contributes to prostate cancer progression through HNF1B co-option of TMPRSS2-ERG

N Giannareas, Q Zhang, X Yang, R Na, Y Tian… - Nature …, 2022 - nature.com
Genome-wide association studies have identified 270 loci conferring risk for prostate cancer
(PCa), yet the underlying biology and clinical impact remain to be investigated. Here we …

Androgen-driven fusion genes and chimeric transcripts in prostate cancer

M Scaravilli, S Koivukoski, L Latonen - Frontiers in Cell and …, 2021 - frontiersin.org
Androgens are steroid hormones governing the male reproductive development and
function. As such, androgens and the key mediator of their effects, androgen receptor (AR) …

Oncogenic ETS factors in prostate cancer

TR Nicholas, BG Strittmatter, PC Hollenhorst - Prostate Cancer: Cellular …, 2019 - Springer
Prostate cancer is unique among carcinomas in that a fusion gene created by a
chromosomal rearrangement is a common driver of the disease. The TMPRSS2/ERG …